TG Therapeutics Inc. (NASDAQ: TGTX) entered into a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital, according to a company statement. The biotechnology company will use the proceeds to repay its existing $250 million credit facility, resulting in a net capital raise of $500 million.

The new facility includes an option for up to an additional $250 million of incremental capital, potentially bringing the total facility size to $1 billion, subject to mutual agreement between TG Therapeutics and Blue Owl.

In connection with the financing, TG Therapeutics' board authorized an expansion of the company's share repurchase program from $100 million to $300 million. As of March 18, 2026, the company had repurchased approximately $38 million of common stock under its existing program at an average price of $28.98 per share.

"This financing builds on our cash flow positive business and provides substantial non-dilutive capital to support opportunistic share repurchases and business development, while continuing to invest in the growth of BRIUMVI and advancement of our pipeline," stated Michael S. Weiss, chairman and chief executive officer.

TG Therapeutics is a commercial-stage biotechnology company focused on treatments for B-cell diseases. The company has received U.S. Food and Drug Administration approval for BRIUMVI, a treatment for adult patients with relapsing forms of multiple sclerosis.

Additional details regarding the credit facility will be filed with the Securities and Exchange Commission on Form 8-K, the company stated.